Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)

Launched by AHEPA UNIVERSITY HOSPITAL · Aug 8, 2020

Keywords

ClinConnect Summary

This is a single-arm prospective observational study aiming to explore the safety and efficacy of switching from direct oral anticoagulants (DOAC) to low molecular weight heparin (LMWH) in cancer patients with atrial fibrillation (AF) during antineoplastic therapy or for a maximum time period of 6 months.

AF is the most common sustained arrhythmia; it affects 1.5% to 2% of the general population, and this prevalence increases to 10% at 80 years of age and to 18% at 85 years of age. Given the increasing occurrence of malignancies in the elderly and the coexistence of other conditions predis...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects diagnosed with cancer other than basal-cell or squamous-cell skin cancer which was objectively confirmed and are programmed for antineoplastic treatment
• • 2. Subjects between 18 to 75 years of age at inclusion
• • 3. Subjects must weigh at least 40 kg at inclusion
• • 4. Subjects receiving direct oral anticoagulant treatment (rivaroxaban, dabigatran, apixaban, edoxaban) for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
• Exclusion Criteria:
• • 1. Patients that have active or serious bleeding within the previous two weeks
• • 2. Patients that have conditions associated with high bleeding risk (active peptic ulcer, recent neurosurgery
• • 3. Patients with platelet count below 50000 per cubic millimeter
• • 4. Patients who have contraindications to heparin (heparin-induced thrombocytopenia)
• • 5. Patients with calculated creatinine clearance \< 30 ml/min using the Cockcroft-Gault formula
• • 6. Women who are pregnant
• • 7. Life expectancy less than 6 months
• • 8. Anticoagulation contraindications
• • 9. Recent brain surgery within 6 months
• • 10. Vascular surgery within 6 months